image
Healthcare - Medical - Devices - NASDAQ - US
$ 2.84
-8.97 %
$ 13.5 M
Market Cap
-0.42
P/E
1. INTRINSIC VALUE

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.[ Read More ]

The intrinsic value of one VVOS stock under the base case scenario is HIDDEN Compared to the current market price of 2.84 USD, Vivos Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VVOS

image
FINANCIALS
13.8 M REVENUE
-13.87%
-17.3 M OPERATING INCOME
30.90%
-13.6 M NET INCOME
43.04%
-11.9 M OPERATING CASH FLOW
39.01%
-853 K INVESTING CASH FLOW
7.68%
10.9 M FINANCING CASH FLOW
0.00%
3.86 M REVENUE
-4.79%
-2.5 M OPERATING INCOME
-29.08%
-2.62 M NET INCOME
-35.54%
-4.19 M OPERATING CASH FLOW
-37.37%
-192 K INVESTING CASH FLOW
-220.00%
3.79 M FINANCING CASH FLOW
-48.82%
Balance Sheet Decomposition Vivos Therapeutics, Inc.
image
Current Assets 2.46 M
Cash & Short-Term Investments 1.64 M
Receivables 202 K
Other Current Assets 616 K
Non-Current Assets 8.27 M
Long-Term Investments 0
PP&E 4.7 M
Other Non-Current Assets 3.57 M
Current Liabilities 7.29 M
Accounts Payable 2.14 M
Short-Term Debt 948 K
Other Current Liabilities 4.2 M
Non-Current Liabilities 3.03 M
Long-Term Debt 1.52 M
Other Non-Current Liabilities 1.51 M
EFFICIENCY
Earnings Waterfall Vivos Therapeutics, Inc.
image
Revenue 13.8 M
Cost Of Revenue 5.53 M
Gross Profit 8.27 M
Operating Expenses 24.9 M
Operating Income -17.3 M
Other Expenses -3.71 M
Net Income -13.6 M
RATIOS
59.93% GROSS MARGIN
59.93%
-125.32% OPERATING MARGIN
-125.32%
-98.42% NET MARGIN
-98.42%
-3304.87% ROE
-3304.87%
-126.59% ROA
-126.59%
-1954.35% ROIC
-1954.35%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Vivos Therapeutics, Inc.
image
Net Income -13.6 M
Depreciation & Amortization 621 K
Capital Expenditures -803 K
Stock-Based Compensation 0
Change in Working Capital 2.86 M
Others 27 K
Free Cash Flow -12.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Vivos Therapeutics, Inc.
image
VVOS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Vivos Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Jun 20, 2023
Bought 7.42 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 14000
0.53 USD
1 year ago
Jun 16, 2023
Bought 2.65 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 5000
0.53 USD
1 year ago
Jun 16, 2023
Bought 5.4 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 10000
0.54 USD
1 year ago
Jun 15, 2023
Bought 10.5 USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 21
0.5 USD
1 year ago
Jun 14, 2023
Bought 4.9 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 10000
0.49 USD
1 year ago
Dec 23, 2022
Bought 10 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 20000
0.5 USD
2 years ago
May 31, 2022
Bought 16.2 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 8000
2.03 USD
3 years ago
Sep 21, 2021
Bought 21.5 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 5000
4.31 USD
3 years ago
Aug 17, 2021
Bought 15 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 5000
3 USD
3 years ago
May 25, 2021
Bought 5.29 K USD
Amman Bradford K.
Chief Financial Officer
+ 1000
5.29 USD
3 years ago
May 25, 2021
Bought 21.5 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 4000
5.38 USD
3 years ago
Dec 24, 2020
Bought 7.38 K USD
Amman Bradford K.
Chief Financial Officer
+ 1000
7.38 USD
3 years ago
Dec 23, 2020
Bought 7.27 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 1000
7.2669 USD
3 years ago
Dec 11, 2020
Bought 4.25 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 500
8.5 USD
7. News
Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call Participants Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets. Operator Good day, everyone, and welcome to the Vivos Therapeutics Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 2 days ago
Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3 Vivos Therapeutics (NASDAQ:VVOS), a medical technology targeting sleep issues such as obstructive sleep apnea (OSA) and snoring, had a strong third quarter marked by higher revenue and reduced operating expenses.  Revenue increased 17% year-over-year to $3.9 million compared to $3.3 million in the same period last year. proactiveinvestors.com - 2 days ago
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. globenewswire.com - 3 days ago
Vivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatment Vivos Therapeutics (NASDAQ:VVOS) announced that the American Medical Association (AMA) has granted new CPT codes for the company's Vivos CARE oral medical devices. Effective January 1, 2025, these codes will streamline insurance coverage and reimbursement for Vivos' devices, designed to treat obstructive sleep apnea (OSA) in both adults and children. proactiveinvestors.com - 1 month ago
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children globenewswire.com - 1 month ago
Vivos Therapeutics raises $4.3 from institutional investors Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into definitive purchase agreements with institutional investors to raise proceeds of $4.3 million through the issuance and sale of an aggregate of 1,363,812 shares at $3.15 each. The company said that no stock purchase warrants are being issued in this at-the-market offering. proactiveinvestors.com - 1 month ago
Vivos Therapeutics' oral device approved by FDA for pediatric sleep apnea treatment Vivos Therapeutics (NASDAQ:VVOS) announced that it has received US Food and Drug Administration (FDA) approval to treat moderate to severe obstructive sleep apnea (OSA) in children aged 6 to 17 using its proprietary oral medical device. This non-invasive, orthodontic-based solution offers an alternative to traditional treatments like adenotonsillectomy, which may not always be effective long-term. proactiveinvestors.com - 1 month ago
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model globenewswire.com - 1 month ago
3 Trending Biotech Penny Stocks Biotech stocks are some of my favorite stocks to watch and invest in for a couple of reasons. 247wallst.com - 2 months ago
Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q2 2024 Earnings Conference Call August 14, 2024 5:00 PM ET Company Participants John Lee - Vivos' Executive Vice President of Marketing Kirk Huntsman - Chairman & Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Do Kim - Water Tower Research Lucas Ward - Ascendiant Incorporated Operator Good day, everyone, and welcome to the Vivos Second Quarter 2024 Earnings Conference Call. [Operator Instructions] This conference is being recorded, and a replay of today's call will be available in Investor Relations section of Vivos' website and will be remaining posted there for the next 30 days. seekingalpha.com - 3 months ago
Vivos Therapeutics boosts Q2 revenue, cuts operating losses amid new strategic partnerships Vivos Therapeutics (NASDAQ:VVOS) reported solid financial numbers for the second quarter of 2024 with a 19% increase in revenue. The company reported a revenue of $4.1 million compared to the $3.4 million reported in the same quarter of 2023, which the company said was primarily driven by increased sales of Vivos appliances and higher service revenue from Vivos Integrated Provider (VIP) enrollments. proactiveinvestors.com - 3 months ago
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today reported financial results and operating highlights for the second quarter and six months ended June 30, 2024. globenewswire.com - 3 months ago
8. Profile Summary

Vivos Therapeutics, Inc. VVOS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 13.5 M
Dividend Yield 0.00%
Description Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Contact 9137 Ridgeline Boulevard, Highlands Ranch, CO, 80129 https://vivos.com
IPO Date Dec. 11, 2020
Employees 114
Officers Ms. Ruth Hembree Senior Vice President of Practice Services Ms. Stephanie Huebner Senior Vice President of Dental Service Integration Mr. Bradford K. Amman Chief Financial Officer, Treasurer & Secretary Mr. John Ballard Senior Vice President of Technology Ms. Susan McCullough Co-Founder & Executive Vice President of Operations Mr. R. Kirk Huntsman Co-Founder, Chairman of the Board & Chief Executive Officer Mr. Nicholas M. DeGennaro Senior Vice President of Medical Integration Division Mr. Todd Huntsman Co-Founder & Senior Vice President of Product and Technology Ms. RaeAnn Byrnes Co-Founder and Senior Vice President of Events & Clinical Advisory Services